New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management

New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management

Despite improving diagnostic possibilities, the incidence of prostate cancer is increasing, but we are not able to reduce the mortality rate. While PSA, 4K score, PCA3 and other urinary markers, ExoDX, SelectMDX, Confirm MDx or MiPS tests are used to identify potential prostate cancer carriers, Deci...

Full description

Saved in:
Bibliographic Details
Main Authors: Milan Kral, Daniela Kurfurstova, Pavel Zemla, Martin Elias, Jan Bouchal
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Oncology
Subjects:
prostate
cancer
biomarker
test
treatment
prognosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1542511/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items